Loading viewer...
investor_presentation
Format: PDF investor_presentation
Cortexyme presents its clinical pipeline focused on atuzaginstat, a gingipain inhibitor for Alzheimer's disease, with pivotal Phase 2/3 GAIN trial data expected in November 2021. The company outlines its disruptive mechanism of action targeting P. gingivalis infection, expanding pipeline including Parkinson's and coronavirus programs, and strong capital position with $153.5M in cash.
investor_presentation
22 Pages
ideaForge Technology Limited
investor_presentation
Alpha Bank